The complement factor H-related protein-5 (CFHR5) exacerbates pathological bone formation in ankylosing spondylitis
- Authors
- Lee, Ji-Hyun; Lee, Seung Hoon; Jeon, Chanhyeok; Han, Jinil; Kim, Sang-Hyon; Youn, Jeehee; Park, Ye-Soo; Kim, Tae-Jong; Kim, Jong-Seo; Jo, Sungsin; Kim, Tae-Hwan; Son, Chang-Nam
- Issue Date
- Apr-2024
- Publisher
- SPRINGER HEIDELBERG
- Keywords
- CFHR5; AS; Mineralization; Osteoprogenitors; Pathological bone formation
- Citation
- JOURNAL OF MOLECULAR MEDICINE-JMM, v.102, no.4, pp 571 - 583
- Pages
- 13
- Journal Title
- JOURNAL OF MOLECULAR MEDICINE-JMM
- Volume
- 102
- Number
- 4
- Start Page
- 571
- End Page
- 583
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26388
- DOI
- 10.1007/s00109-024-02428-6
- ISSN
- 0946-2716
1432-1440
- Abstract
- Ankylosing spondylitis (AS) is a chronic inflammatory disease, characterized by excessive new bone formation. We previously reported that the complement factor H-related protein-5 (CFHR5), a member of the human factor H protein family, is significantly elevated in patients with AS compared to other rheumatic diseases. However, the pathophysiological mechanism underlying new bone formation by CFHR5 is not fully understood. In this study, we revealed that CFHR5 and proinflammatory cytokines (TNF, IL-6, IL-17A, and IL-23) were elevated in the AS group compared to the HC group. Correlation analysis revealed that CFHR5 levels were not significantly associated with proinflammatory cytokines, while CFHR5 levels in AS were only positively correlated with the high CRP group. Notably, treatment with soluble CFHR5 has no effect on clinical arthritis scores and thickness at hind paw in curdlan-injected SKG, but significantly increased the ectopic bone formation at the calcaneus and tibia bones of the ankle as revealed by micro-CT image and quantification. Basal CFHR5 expression was upregulated in AS-osteoprogenitors compared to control cells. Also, treatment with CFHR5 remarkedly induced bone mineralization status of AS-osteoprogenitors during osteogenic differentiation accompanied by MMP13 expression. We provide the first evidence demonstrating that CFHR5 can exacerbate the pathological bone formation of AS. Therapeutic modulation of CFHR5 could be promising for future treatment of AS.Key messagesSerum level of CFHR5 is elevated and positively correlated with high CRP group of AS patients.Recombinant CFHR5 protein contributes to pathological bone formation in in vivo model of AS.CFHR5 is highly expressed in AS-osteoprogenitors compared to disease control.Recombinant CFHR5 protein increased bone mineralization accompanied by MMP13 in vitro model of AS.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Natural Sciences > Department of Biology > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26388)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.